Current Issue

Dec 2022View Current Issue

Background: Controversy has been reported concerning the extent of lymphadenectomy during esophageal adenocarcinoma (EAC) resection surgery in the era of multimodal therapy. Due to unfavorable biology, there is potential for the neoplasia to persist after neoadjuvant therapy. Extended lymphadenectomy might bring a survival advantage to these patients. This systematic review and meta-analysis evaluates whether the extension of lymphadenectomy has impact on overall survival (OS) in patients with EAC submitted to esophagectomy preceded by neoadjuvant therapy.

Safety and Efficacy of Gelatin-Thrombin Matrix Sealants (Floseal®) for Hemostasis During Liver Resection (with video)
Satoshi Okubo, Junichi Shindoh, Masaru Matsumura, Masaji Hashimoto
Article DOI: 10.21614/sgo-518
Read article

Background: The efficacy of gelatin-thrombin matrix sealants (Floseal®) for hemostasis has been well described in the field of cardiovascular surgery, but data supporting its safety and efficacy in liver surgery remains lacking.

Methods: The surgical outcomes of 83 consecutive patients in whom Floseal® was applied during hepatectomy were reviewed. The severity of bleeding before and after the application of Floseal® was graded according to the Validated Intraoperative Bleeding (VIBe) Scale.

Results: Flo....[more]

Evolution of Liver Fibrosis in Patients with HCV Chronic Infection Treated with Direct-Acting Antivirals
Andreea Franculescu-Bertea, Ionel Copaci, Elena Laura Iliescu, Laurentiu Micu
Article DOI: 10.21614/sgo-531
Read article

Background: HCV chronic infection is a leading cause of end-stage liver disease and liver transplantation. The aim of our study was to assess the benefits of novel anti-HCV therapeutic approaches in obtaining viral clearance, in reducing liver inflammation, in regression of fibrosis, and improvement of liver-related morbidity and mortality.

Material and methods: We performed an observational, prospective, non-interventional study in 260 patients with HCV chronic infection and advanced liver fibrosis (F3 and Child class A liver cirrhosis), ....[more]

Outcomes of Surgical Resection of Pancreatic Cystic Neoplasms Based on the European Expert Consensus Statement: A Prospective Observ....
Alaaedin Ramadan, Tamer A.A.M. Habeeb, Aristotelis Kechagias, Arda Isik, Alberto Aiolfi, Shady E. Shaker, Amr Samir, Mahmoud M. Sheded, Mohamed Ragab Khalifa, Rasha Haggag, Adel Bakry, Mohamed Elnemr, Walid A. Mawla
Article DOI: 10.21614/sgo-515
Read article

Background: The most common types of true epithelial exocrine pancreatic cystic neoplasms are serous cystic neoplasms (SCNs), mucinous cystic neoplasms (MCNs), intra-ductal papillary mucinous neoplasms (IPMNs), and solid pseudo-papillary neoplasms (SPPNs). Both open and laparoscopic pancreatic surgeries are major procedures with significant morbidity and mortality rates. This study aimed to determine the outcomes of laparoscopic pancreatic surgery in managing true exocrine epithelial pancreatic cystic neoplasms in terms of postoperative pancreatic fistula and recu....[more]

C-KIT Negative Gastrointestinal Stromal Tumors: Challenges of Management and Prognosis
Mohamed Atef ElKordy, Fady Rashad Selim, Amani A. Abou Bakr, Eman D. ElDesouky, Foad AbdElShaheed Foad
Article DOI: 10.21614/sgo-517
Read article

Background: Gastrointestinal stromal tumours (GISTs) are uncommon sarcomas. Surgery and target therapy are the primary modalities in treating GIST. KIT expression is the cornerstone in diagnosis of GIST, yet its expression is absent in a small percent of GISTs. The precise behaviour and treatment effects, particularly target therapy, and the prognosis of these cases are unclear; hence this study was designed to investigate them.


Methods: In the current retrospective cohort research, all patients with GIST who presented and w....[more]

Search The Journal

Video Abstracts

For Authors

Journal Subscriptions

Current Issue

Dec 2022


Instructions for authors
Online submission
ISSN: 2559 - 723X (print)

e-ISSN: 2601 - 1700 (online)

ISSN-L: 2559 - 723X

Journal Abbreviation: Surg. Gastroenterol. Oncol.

Surgery, Gastroenterology and Oncology (SGO) is indexed in:
  • DOI/Crossref
  • Google Scholar
  • SCImago
  • Harvard Library
  • Open Academic Journals Index (OAJI)

Journal Metrics

Time to first editorial decision: 25 days
Rejection rate: 61%
CiteScore: 0.2

Meetings and Courses in 2023
Meetings and Courses in 2022
Meetings and Courses in 2021
Meetings and Courses in 2020
Meetings and Courses in 2019
Verona expert meeting 2019

Creative Commons License
Surgery, Gastroenterology and Oncology applies the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits readers to copy and redistribute the material in any medium or format, remix, adapt, build upon the published works non-commercially, and license the derivative works on different terms, provided the original material is properly cited and the use is non-commercial. Please see: